Publications

Clinical Trial
Journal Article Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S.
Ppublish 2408 citations
Electronic publication date
April 24, 1997

View on Pubmed.gov 9110909 | View on doi.org 10.1056/NEJM199...

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Search for publications in this journal N Engl J Med - 336(17):1216-22

Abstract

BACKGROUND

There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease.

METHODS

We conducted a double-blind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer's disease of moderate severity. A total of 341 patients received the selective monoamine oxidase inhibitor selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2000 IU a day), both selegiline and alpha-tocopherol, or placebo for two years. The primary outcome was the time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3).

RESULTS

Despite random assignment, the baseline score on the Mini-Mental State Examination was higher in the placebo group than in the other three groups, and this variable was highly predictive of the primary outcome (P<0.001). In the unadjusted analyses, there was no statistically significant difference in the outcomes among the four groups. In analyses that included the base-line score on the Mini-Mental State Examination as a covariate, there were significant delays in the time to the primary outcome for the patients treated with selegiline (median time, 655 days; P=0.012), alpha-tocopherol (670 days, P=0.001) or combination therapy (585 days, P=0.049), as compared with the placebo group (440 days).

CONCLUSIONS

In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.

References

No references provided.

Cited by 2408 citations (total)

Journal Article Review

Memory, thinking, and aging. What we know about what we know.

Electronic publication date December 31, 1997

Search for publications in this journal West J Med

L Teri [...] R G Logsdon et al.

Cognition is the foundation that underlies all daily activities, from the most basic to the most complex. Successful aging depends,...

Journal Article Research Support, Non-U.S. Gov't

Prevalence of potentially reversible dementias and actual reversibility in a memory clinic cohort.

Electronic publication date October 22, 1998

Search for publications in this journal CMAJ

S Freter [...] A M Clarfield et al.

BACKGROUND

Although clinics for the evaluation of cognitive dysfunction have typically emphasized the detection and treatment of the reversible causes of...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Substances